Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Cash from Financing Activities (2016 - 2025)

Vanda Pharmaceuticals' Cash from Financing Activities history spans 14 years, with the latest figure at -$640000.0 for Q4 2025.

  • For Q4 2025, Cash from Financing Activities fell 312.9% year-over-year to -$640000.0; the TTM value through Dec 2025 reached -$2.9 million, down 1774.84%, while the annual FY2025 figure was -$2.9 million, 1774.84% down from the prior year.
  • Cash from Financing Activities for Q4 2025 was -$640000.0 at Vanda Pharmaceuticals, down from -$517000.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $1.8 million in Q1 2021 and bottomed at -$1.3 million in Q1 2025.
  • The 4-year median for Cash from Financing Activities is $64500.0 (2022), against an average of $101916.7.
  • The largest annual shift saw Cash from Financing Activities skyrocketed 286.01% in 2021 before it tumbled 312.9% in 2025.
  • A 4-year view of Cash from Financing Activities shows it stood at $1.0 million in 2021, then crashed by 41.88% to $605000.0 in 2022, then crashed by 125.62% to -$155000.0 in 2024, then crashed by 312.9% to -$640000.0 in 2025.
  • Per Business Quant, the three most recent readings for VNDA's Cash from Financing Activities are -$640000.0 (Q4 2025), -$517000.0 (Q3 2025), and -$425000.0 (Q2 2025).